Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

93556

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pharmaceutical Price Regulation Scheme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions (a) he or (b) officials in his Department have had on reinvesting the industry rebate payments under the current Pharmaceutical Price Regulation Scheme into (i) healthcare services and (ii) medicines expenditure.
tabling member constituency	Cambridge
tabling member printed	Dr Julian Huppert
uin	210807
answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The Pharmaceutical Price Regulation Scheme (PPRS) as agreed with the Association of the British Pharmaceutical Industry (ABPI) does not cover the onward financial flows of payments to the National Health Service which are subject to the Government accounting and budgeting rules in the normal way. In particular there was no agreement to hypothecate PPRS payments. The Department has subsequently had a number of discussions with the ABPI and NHS England about the onward financial flows.</p><p> </p><p> </p><p> </p><p>In respect of England, the anticipated payments in 2014-15 have been passed on to NHS England through the mandate and as such were included within commissioner allocations. The same is expected to apply in 2015-16. This means that the effect of the deal is felt across the NHS through the general funding allocations to clinical commissioning groups.</p><p> </p><p> </p><p> </p><p>The Government is committed to improving access to clinically and cost-effective medicines including innovative new medicines. As part of implementing the PPRS, NHS England and the ABPI are discussing how best to improve access to and optimise patient outcomes from these medicines.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/10/2014 15:38:43 answering member 4020 label Biography information for George Freeman
tabling member	3931 label Biography information for Dr Julian Huppert

93563

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Surgical Mesh Implants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will review his policy on polypropylene transvaginal mesh implants in response to recent court judgements in the US.
tabling member constituency	Newcastle upon Tyne East
tabling member printed	Mr Nicholas Brown
uin	210655
answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>A working group, chaired by NHS England and including patient representatives, clinical representatives, the Department and the Medicines and Healthcare Products Regulatory Agency, has been set up to understand and address the concerns which have been raised about transvaginal mesh implants.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/10/2014 15:19:50 answering member 4020 label Biography information for George Freeman
tabling member	523 label Biography information for Mr Nicholas Brown

93568

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what funding his Department provides for businesses and organisations conducting research into the benefits of natural products in cancer therapy and treatment.
tabling member constituency	Belfast North
tabling member printed	Mr Nigel Dodds
uin	210719
answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>The Government has funding mechanisms in place for research and development relating to cancer treatments.</p><p> </p><p> </p><p> </p><p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including the use of natural products in cancer treatment. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>The NIHR is investing £16 million over five years (to 2017) in 14 Experimental Cancer Medicine Centres (ECMCs) across England with joint funding from Cancer Research UK. These centres bring together laboratory and clinical patient-based research to speed up the development of innovative cancer therapies and individualise patient treatment. Researchers at the Leicester ECMC are currently looking at whether curcumin – found in turmeric – can improve drug response in patients with advanced bowel cancer.</p><p> </p><p> </p><p> </p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which bridges the gap between preclinical studies and evidence of clinical efficacy. The aim is to secure the progress of new technologies and interventions through their early clinical trials and onto larger, later clinical trials. The programme is funded by the Medical Research Council (MRC) and the NIHR and is not currently funding any studies of the use of natural products in cancer treatment.</p><p> </p><p> </p><p> </p><p>Other sources of funding include the Biomedical Catalyst, which is a funding programme jointly operated by the MRC and Innovate UK. The programme provides responsive and effective support for the best translational life science opportunities arising. Grants are available to UK academics and small and medium enterprises seeking to move their research more quickly from discovery to commercialisation.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 22/10/2014 15:10:04 answering member 4020 label Biography information for George Freeman
tabling member	1388 label Biography information for Lord Dodds of Duncairn

93570

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Diabetes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost was of providing free prescriptions to people with diabetes in (a) England and (b) Havering in 2013-14.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	210702
answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>Information is not available in the format requested</p><p> </p><p> </p><p> </p><p>Diabetes and Myxoedema are two of the specific conditions which entitle individuals to apply for a medical exemption certificate to provide them with exemption from prescription charges.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 210703 question first answered 22/10/2014 15:33:24 answering member 4020 label Biography information for George Freeman
tabling member	1447 label Biography information for Andrew Rosindell

93571

registered interest
date	15/10/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Thyroid Gland
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost was of providing free prescriptions to people with myxodema in (a) England and (b) Havering in 2013-14.
tabling member constituency	Romford
tabling member printed	Andrew Rosindell
uin	210703
answer	answer is ministerial correction date of answer 22/10/2014 answer text <p>Information is not available in the format requested</p><p> </p><p> </p><p> </p><p>Diabetes and Myxoedema are two of the specific conditions which entitle individuals to apply for a medical exemption certificate to provide them with exemption from prescription charges.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 210702 question first answered 22/10/2014 15:33:24 answering member 4020 label Biography information for George Freeman
tabling member	1447 label Biography information for Andrew Rosindell